RIPK1-IN-17

Overview

RIPK1-IN-17 is an orally active, selective RIPK1 inhibitor ( K d = 17 nM) and shows no significant inhibition to RIPK3 . RIPK1-IN-17 specifically inhibits necroptosis rather than apoptosis by inhibiting RIPK1 , RIPK3 , and MLKL phosphorylation. RIPK1-IN-17 protects mice from hypothermia and death. RIPK1-IN-17 can be used for the study of necroptosis-related diseases such as inflammatory response syndrome (SIRS).

Application

Products | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Obesity | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > RIP kinase | Products > Signaling Pathways > Necroptosis | Products > Signaling Pathways > Mixed Lineage Kinase

Product Information

• Catalog No.: HY-157039
• CAS No.: 3033385-59-7
• Molecular Formula: C26H19F4N3O3S
• Molecular Weight: 529.51
• Purity: 97.09%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source